FGF19 and acute myeloid leukemia: Treatment with recombinant FGF19 for 24 hours significantly inhibited mRNA expressions of Lcn2 and Saa1 in a dose-dependent manner with a maximal effect at 50 ng/ml in AML-12 cells (Supplementary Fig. S1).